Clinical Trials

Primary Breast Cancer

NCT03939871 2020-06-23

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

30 enrolled

Hormone Receptor Positive Advanced Breast Cancer

NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

20 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04307147 2020-03-13

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

316 enrolled

Breast Neoplasms

NCT04302441 2020-03-10

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

550 enrolled

Breast Neoplasms

NCT03656094 2019-12-09

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

98 enrolled

Non-small Cell Lung Cancer Metastatic

NCT04143906 2019-10-30

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

200 enrolled

Breast Neoplasms

NCT04021992 2019-08-06

GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

48 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03997539 2019-06-25

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

256 enrolled

Breast Neoplasms

NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

30 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Phase NA Unknown

48 enrolled

HER2 Positive Breast Cancer

NCT03932526 2019-04-30

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

184 enrolled

Triple Negative Breast Neoplasms

NCT03703427 2018-10-12

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

200 enrolled

Pathologic Residual Cancer Cells

NCT03656393 2018-09-04

RCTACSCNSCLC

48 enrolled

NSCLC

NCT03188159 2018-03-29

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

36 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03423849 2018-02-06

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Phase 2/3 Unknown

200 enrolled

Breast Neoplasms

NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

300 enrolled

Breast Neoplasms, Genetic Predisposition to Disease

NCT02489409 2017-07-17

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

120 enrolled

Breast Neoplasms

NCT02144194 2017-02-09

TNM

65 enrolled

Breast Neoplasms

NCT03006614 2017-01-16

PERS

320 enrolled

Breast Neoplasms

NCT02579564 2016-10-21

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

134 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01683175 2016-10-20

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

94 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02897986 2016-09-13

PROVIN

Phase 1 Unknown

54 enrolled

Tumor-Agnostic

Neoplasms

NCT02665702 2016-01-28

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas